Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 602

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Tara Rajendran, MBBS, Prasad Pramod Rane, MPH, Krishna Prasad, MBBS, MD(Internal MDcine), DM (Oncology)

Blood (2019) 134 (Supplement_1): 5913.

https://doi.org/10.1182/blood-2019-125978

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4001.

https://doi.org/10.1182/blood-2019-126951

Published: 2019

Journal Articles

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Blood (2019) 134 (Supplement_1): 3820.

https://doi.org/10.1182/blood-2019-122275

Published: 2019

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

Journal Articles

Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients

Tracy Westley, MPH, Dimitrios Tomaras, MSc, Eric Strati, PharmD, Donna Skerrett, MD MS, Anna Forsythe, PharmD, MBA, MMSc, Gabriel Tremblay, DBA, MSc, BS

Blood (2019) 134 (Supplement_1): 4545.

https://doi.org/10.1182/blood-2019-131098

Published: 2019

Journal Articles

The Use of Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Gastrointestinal Graft-Versus-Host-Disease in Adults and Children

Sadeghi Behnam, PhD MD, Remberger Mats, PhD, Per Frisk, MD PhD, Britt-Marie Frost, MD PhD, Olle Ringden, Professor, Britt Gustafsson, MD PhD

Blood (2019) 134 (Supplement_1): 4456.

https://doi.org/10.1182/blood-2019-122674

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM

Blood (2019) 134 (Supplement_1): 2914.

https://doi.org/10.1182/blood-2019-128755

Published: 2019

Journal Articles

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2834.

https://doi.org/10.1182/blood-2019-123150

Published: 2019

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

Journal Articles

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Enrique M. Ocio, Yvonne A. Efebera, MD MPH, Miquel Granell, MD, Roman Hajek, MD, Vladimir Maisnar, MD, Lionel Karlin, MD, María-Victoria Mateos, MD PhD, Paul G. Richardson, MD, Albert Oriol, MD, Stefan Norin, MD, Malin Sydvander, MSc, Jakob Obermüller, MSc, Luděk Pour, MD

Blood (2019) 134 (Supplement_1): 3124.

https://doi.org/10.1182/blood-2019-124815

Published: 2019

Journal Articles

Portal Vein Thrombosis: A Single Institution Experience

Rayli Pichardo, MD, Vatsala Katiyar, MD, Ishaan Vohra, MD, Yazan Abu Omar, Sanjay Patel

Blood (2019) 134 (Supplement_1): 4961.

https://doi.org/10.1182/blood-2019-127556

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

Wenrui Yang, MD, Bing Han, MD PhD, Hong Chang, MD, Bingyi Wu, MD, Fankai Meng, Dexiang Ji, MD, Yingmei Li, MD, Zhengjin Zheng, MD, Yan Fei, Jianping Shen, MD, Ping Hu, MD, Jianxiang Wang, MD, Fengkui Zhang, MD

Blood (2019) 134 (Supplement_1): 5020.

https://doi.org/10.1182/blood-2019-126441

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Splanchnic Venous Thrombosis (SVT) Case Series at a Tertiary Care Hospital: Exploring Clinical Presentation, Diagnosis, Etiology, Thrombophilia, Treatment, and Outcome

Mohammed Abdullah Alsheef, MD, Mukhtar Alomar, PharmD, Ghaydaa Juma Kullab, MD, Abdurahman AlTwaijri, MD, Hassan Maymani, MD, Abdul Rehman Z. Zaidi, MBBS

Blood (2019) 134 (Supplement_1): 4954.

https://doi.org/10.1182/blood-2019-128289

Published: 2019

Journal Articles

ADAMTS13 Immunohistochemical Expression in Normal and Diseased Equine Tissues

Sherri Flax, MD

Blood (2019) 134 (Supplement_1): 4925.

https://doi.org/10.1182/blood-2019-127407

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients

The Use of Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Gastrointestinal Graft-Versus-Host-Disease in Adults and Children

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Portal Vein Thrombosis: A Single Institution Experience

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Splanchnic Venous Thrombosis (SVT) Case Series at a Tertiary Care Hospital: Exploring Clinical Presentation, Diagnosis, Etiology, Thrombophilia, Treatment, and Outcome

ADAMTS13 Immunohistochemical Expression in Normal and Diseased Equine Tissues

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only